>
产品中心 >
Antibody_set >
academy biomed/[P15] Ultra Pure Human Apolipoprotein CIII (ApoCIII)/0.2 mg/33P-UP202
![academy biomed/[P15] Ultra Pure Human Apolipoprotein CIII (ApoCIII)/0.2 mg/33P-UP202](https://www.ebiomall.cn/images/academybiomed/P15_300x300.jpg)
| Concentration: | 1 mg / ml, determined by the Lowry method |
| Source: | From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens. |
| Purification: | After series ultracentrifugations, Very Low Density Lipoprotein (VLDL) is isolated from human plasma. Apo CIII is purified from delepidated VLDL, followed by gel-filtration and DEAE-Sepharcyl chromatography. Minor impurities of other apo-proteins are then removed by antibody-Sepharose™ affinity column. |
| Purity: | ≥ 99% by SDS-PAGE |
| Buffer: | In 10 mM Tris-HCl, 0.15 M NaC1, 0.5 mM EDTA, 0.02 % NaN3, pH 8.0 |
| Storage: | -20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing. |
*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Importance
Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).
It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)
Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.
Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .
Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.
Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.
Citations
| [P14][P15] | 2017 | Toth, Christopher A.; Kuklenyik, Zsuzsanna; Jones, Jeffrey I.; Parks, Bryan A.; Gardner, Michael S.; Schieltz, David M. et al. (2017): On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins. In Journal of proteomics 150, pp. 258–267. DOI: 10.1016/j.jprot.2016.09.011. |
| [P14][P15] | 2016 | Koska, Juraj; Yassine, Hussein; Trenchevska, Olgica; Sinari, Shripad; Schwenke, Dawn C.; Yen, Frances T. et al. (2016): Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. In Journal of lipid research 57 (5), pp. 894–905. DOI: 10.1194/jlr.P064816. |
| [P14][P15] | 2013 | Zheng, Chunyu; Azcutia, Veronica; Aikawa, Elena; Figueiredo, Jose-Luiz; Croce, Kevin; Sonoki, Hiroyuki et al. (2013): Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. In European Heart Journal 34 (8), pp. 615–624. DOI: 10.1093/eurheartj/ehs271. |
| [P14][P15] | 2011 | Holleboom, Adriaan G.; Karlsson, Helen; Lin, Ruei-Shiuan; Beres, Thomas M.; Sierts, Jeroen A.; Herman, Daniel S. et al. (2011): Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in Man. In Cell metabolism 14 (6), pp. 811–818. DOI: 10.1016/j.cmet.2011.11.005. |
| [P14][P15] | 2010 | Abe, Yasuko; Kawakami, Akio; Osaka, Mizuko; Uematsu, Satoshi; Akira, Shizuo; Shimokado, Kentaro et al. (2010): Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. In Arterioscler Thromb Vasc Biol. 30 (11), pp. 2242–2248. DOI: 10.1161/ATVBAHA.110.210427. |
| [P14][P15] | 2010 | Mazur, Matthew T.; Cardasis, Helene L.; Spellman, Daniel S.; Liaw, Andy; Yates, Nathan A.; Hendrickson, Ronald C. (2010): Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. In Proc Natl Acad Sci USA 107 (17), pp. 7728–7733. DOI: 10.1073/pnas.0910776107. |
| [P14][P15] | 2007 | Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d. |
| [P14][P15] | 2007 | Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d. |
| [P14][P15] | 2006 | Kawakami, Akio; Aikawa, Masanori; Alcaide, Pilar; Luscinskas, Francis W.; Libby, Peter; Sacks, Frank M. (2006): Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. In Circulation 114 (7), pp. 681–687. DOI: 10.1161/CIRCULATIONAHA.106.622514. |
| [P14][P15] | 2006 | Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743. |
| [P14][P15] | 2006 | Schaap, Frank G.; Nierman, Melchior C.; Berbée, Jimmy F. P.; Hattori, Hiroaki; Talmud, Philippa J.; Vaessen, Stefan F. C. et al. (2006): Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. In J. Lipid Res. 47 (10), pp. 2333–2339. DOI: 10.1194/jlr.M500533-JLR200. |
| [P14][P15] | 2005 | Gerritsen, Gery; Rensen, Patrick C. N.; Kypreos, Kyriakos E.; Zannis, Vassilis I.; Havekes, Louis M.; van Willems Dijk, Ko (2005): ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. In J. Lipid Res. 46 (7), pp. 1466–1473. DOI: 10.1194/jlr.M400479-JLR200. |
| [P14][P15] | 2002 | Olin-Lewis, Katherine; Krauss, Ronald M.; La Belle, Michael; Blanche, Patricia J.; Barrett, P. Hugh R.; Wight, Thomas N.; Chait, Alan (2002): ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. In J. Lipid Res. 43 (11), pp. 1969–1977. DOI: 10.1194/jlr.M200322-JLR200. |
